Compare · HIMS vs MEDS
HIMS vs MEDS
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. HIMS focuses on Medical/Nursing Services, while MEDS focuses on Other Pharmaceuticals.
- HIMS is the larger of the two at $4.35B, about 1403.4x MEDS ($3.1M).
- HIMS has been more active in the news (15 items in the past 4 weeks vs 5 for MEDS).
- HIMS has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Hims & Hers Health Inc.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $4.35B
- $3.1M
- 1M return
- -
- -77.82%
- 1Y return
- -
- -98.02%
- Industry
- Medical/Nursing Services
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 15
- 5
- Recent ratings
- 25
- 1
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest HIMS
- Director Payne Christopher D was granted 810 restricted stock units (SEC Form 4)
- Chief Accounting Officer Franklin Jonathan M was granted 102,774 restricted stock units (SEC Form 4)
- Director Wells David B was granted 1,051 restricted stock units (SEC Form 4)
- Director Huberman Andrew D was granted 19,301 restricted stock units (SEC Form 4)
- SEC Form 3 filed by new insider Huberman Andrew D
- Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
- SEC Form 10-Q filed by Hims & Hers Health Inc.
- Hims & Hers Health Inc. filed SEC Form 8-K: Leadership Update
- Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Latest MEDS
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap